Sclerosis News and Research

RSS

Clinical trial to evaluate TAU's stem cell technology for ALS

The ability to produce neuroprotectors, proteins that protect the human brain against neurodegenerative disorders such as Parkinson's and ALS, is the holy grail of brain research. A technology developed at Tel Aviv University does just that, and it's now out of the lab and in hospitals to begin clinical trials with patients suffering from amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease.

21 Sep 2011

African-American men living in low sunlight areas more likely to have Vitamin D deficiency

African-American men living in areas with low sunlight are up to 3 - times more likely to have Vitamin D deficiency than Caucasian men and should take high levels of Vitamin D supplements, according to a new study from Northwestern University Feinberg School of Medicine.

21 Sep 2011

Researchers’ discovery may revolutionize treatment of Lou Gehrig’s disease

A team of researchers from the University of British Columbia and the Vancouver Coastal Health Research Institute have found a key link between prions and the neurodegenerative disease ALS (Amyotrophic Lateral Sclerosis), also known as Lou Gehrig’s disease. The discovery is significant as it opens the door to novel approaches to the treatment of ALS.

20 Sep 2011

Yawning could regulate brain temperature

A study led by Andrew Gallup, a postdoctoral research associate in Princeton University's Department of Ecology and Evolutionary Biology, is the first involving humans to show that yawning frequency varies with the season and that people are less likely to yawn when the heat outdoors exceeds body temperature.

20 Sep 2011

SK Biopharmaceuticals, Mayo Clinic collaborate to develop new treatments for ALS

Mayo Clinic's campus in Florida has entered into a collaborative and sponsored research agreement with SK Biopharmaceuticals of Seoul, South Korea, with the goal of developing new treatments for amyotrophic lateral sclerosis (ALS), or Lou Gehrig's disease. The collaboration marks a new approach to combating a disease that has proved difficult to treat in recent clinical trials.

20 Sep 2011

Mayo Clinic, SK biopharmaceuticals collaborate to discover new ALS drugs

South Korean biotech SK biopharmaceuticals announced yesterday that they signed an agreement to collaborate with the Mayo Clinic for the discovery of new drugs targeting Amyotrophic Lateral Sclerosis.

20 Sep 2011

New report finds decline in clinical trial recruitment for autoimmune disorders

The number of patients recruited to clinical trials for autoimmune disorders has waned in the last ten years, according to a new report available on companiesandmarkets.com.

19 Sep 2011

ALS damages neurons in parts of the brain responsible for cognition and behaviour

Recently published studies by a researcher in the Faculty of Medicine & Dentistry demonstrate that ALS - known as Lou Gehrig's disease - damages neurons in parts of the brain responsible for cognition and behaviour.

17 Sep 2011

Scientists discover new type of spinal cord stem cell

A group led by a University of British Columbia and Vancouver Coastal Health scientist has discovered a type of spinal cord cell that could function as a stem cell, with the ability to regenerate portions of the central nervous system in people with spinal cord injuries, multiple sclerosis or amyotrophic lateral sclerosis.

16 Sep 2011

New cell type could play an important role in spinal cord injury and disease

The Allen Institute for Brain Science announced today the discovery of a new class of cells in the spinal cord that act like neural stem cells, offering a fresh avenue in the search for therapies to treat spinal cord injury and disease.

16 Sep 2011

Synthon announces European approvals for Eplerenone

Synthon has successfully concluded multiple registration procedures for the cardiovascular drug Eplerenone. Synthon has obtained regulatory clearance for the product in nine European countries, for both 25 and 50 mg film coated tablets.

15 Sep 2011

Researchers may have solved 100-year-old puzzle to safely open and close the blood-brain barrier

Cornell University researchers may have solved a 100-year puzzle: How to safely open and close the blood-brain barrier so that therapies to treat Alzheimer's disease, multiple sclerosis and cancers of the central nervous system might effectively be delivered.

14 Sep 2011

FDA grants Orphan Drug Designation for Accentia's Revimmune to prevent GVHD

Accentia Biopharmaceuticals, Inc. and its majority-owned subsidiary, Biovest International, Inc., today jointly announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to Revimmune, the Company's proprietary system-of-care based on high-dose administration of Cytoxan, for the prevention of graft-versus-host disease (GVHD) following bone marrow transplant.

14 Sep 2011

Biotica, Buck Institute collaborate to investigate polyketides in diseases of aging

The Buck Institute for Research on Aging and Biotica Technology Ltd. today announced a three-year collaboration to investigate polyketides in diseases of aging. Building on observations that rapamycin extends healthy lifespan in various species, the collaborators will evaluate rapamycin analogs and other polyketides in a broad range of age-related disease models to identify novel therapeutics.

14 Sep 2011

Walgreens, MDA team up to offer free seasonal flu shots

Nobody likes to get stuck with a needle. But influenza - the flu - is particularly hazardous for those with neuromuscular disease, which is why the Muscular Dystrophy Association (MDA) and Walgreens have teamed up once again to offer free seasonal flu shots now underway for people who have muscular dystrophy and related diseases.

14 Sep 2011

New imaging method could better assess extent of nerve damage

A new imaging technique could help doctors and researchers more accurately assess the extent of nerve damage and healing in a live patient. Researchers at Laval University in Qu-bec and Harvard Medical School in Boston aimed lasers at rats' damaged sciatic nerves to create images of the individual neurons' insulating sheath called myelin.

14 Sep 2011

Health Canada approves Afinitor for treatment of brain tumours caused by TSC in children

Families with children suffering from brain tumours caused by an uncommon genetic disorder known as Tuberous Sclerosis Complex (TSC) have new hope with Health Canada's recent conditional approval of a new therapeutic use for the drug Afinitor (everolimus). Afinitor is the first drug therapy approved in Canada for the treatment of brain tumours caused by TSC in patients three years of age and older.

14 Sep 2011

Roundup: N.J. Governor opts not to cut Medicaid rolls; Seattle council mandates sick leave

Thousands of New Jersey's working poor will keep their health insurance under a new administration proposal to restructure Medicaid, abandoning a controversial plan that would have drastically reduced the number of eligible recipients.

14 Sep 2011

University of Adelaide research focuses on techniques to treat swallowing disorders

A simple function that most of us take for granted - swallowing - is the focus of University of Adelaide research which could help thousands of stroke sufferers around the world.

12 Sep 2011

Bristol-Myers Squibb acquires Amira Pharmaceuticals

Bristol-Myers Squibb Company announced today that it has completed its previously announced acquisition of privately held Amira Pharmaceuticals, Inc., a small-molecule pharmaceutical company focused on the discovery and early development of new drugs to treat inflammatory and fibrotic diseases.

9 Sep 2011

Sclerosis News and Research

Clinical trial to evaluate TAU's stem cell technology for ALS

African-American men living in low sunlight areas more likely to have Vitamin D deficiency

Researchers’ discovery may revolutionize treatment of Lou Gehrig’s disease

Yawning could regulate brain temperature

SK Biopharmaceuticals, Mayo Clinic collaborate to develop new treatments for ALS

Mayo Clinic, SK biopharmaceuticals collaborate to discover new ALS drugs

New report finds decline in clinical trial recruitment for autoimmune disorders

ALS damages neurons in parts of the brain responsible for cognition and behaviour

Scientists discover new type of spinal cord stem cell

New cell type could play an important role in spinal cord injury and disease

Synthon announces European approvals for Eplerenone

Researchers may have solved 100-year-old puzzle to safely open and close the blood-brain barrier

FDA grants Orphan Drug Designation for Accentia's Revimmune to prevent GVHD

Biotica, Buck Institute collaborate to investigate polyketides in diseases of aging

Walgreens, MDA team up to offer free seasonal flu shots

New imaging method could better assess extent of nerve damage

Health Canada approves Afinitor for treatment of brain tumours caused by TSC in children

Roundup: N.J. Governor opts not to cut Medicaid rolls; Seattle council mandates sick leave

University of Adelaide research focuses on techniques to treat swallowing disorders

Bristol-Myers Squibb acquires Amira Pharmaceuticals

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News